Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revamped MCAC to review ICDs

This article was originally published in The Gray Sheet

Executive Summary

Medicare Coverage Advisory Committee will convene Feb. 12 at the Baltimore Convention Center to evaluate "all indications for ICDs," responding to Guidant's request that CMS cover prophylactic implantation of the devices. The meeting will be the first under 1MCAC's revised charter abandoning the use of specialty panels in favor of floating members. The event will feature 15 committee members, with a chair and vice-chair still to be announced. Future meeting participants will be selected from a maximum pool of 100 members, based on expertise and availability. Comments on the ICD meeting are due Jan. 29. With the MCAC Executive Committee step eliminated, CMS estimates it will take roughly 90 days after the meeting to issue a decision memo...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017810

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel